Chimerix Inc financial data

Symbol
CMRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2505 Meridian Parkway, Suite 100, Durham, NC
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 791 % -38.1%
Quick Ratio 9.83 %
Debt-to-equity 13 % +61.6%
Return On Equity -50.8 % -39%
Return On Assets -44.9 % -32.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 89.9M shares +1.18%
Common Stock, Shares, Outstanding 89.9M shares +1.18%
Entity Public Float 93.6M USD -15.8%
Weighted Average Number of Shares Outstanding, Basic 89.7M shares +1.22%
Weighted Average Number of Shares Outstanding, Diluted 89.7M shares +1.22%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 159K USD -86%
Cost of Revenue 0 USD -100%
General and Administrative Expense 20.4M USD -17.6%
Operating Income (Loss) -92.8M USD +3.38%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -24M USD -110%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -83.6M USD +1.53%
Earnings Per Share, Basic -0.95 USD/shares 0%
Earnings Per Share, Diluted -0.95 USD/shares +3.06%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 155K USD +1309%
Inventory, Net 0 USD -100%
Other Assets, Current 2.89M USD -44%
Assets, Current 141M USD -29.8%
Property, Plant and Equipment, Net 281K USD +13.3%
Operating Lease, Right-of-Use Asset 1.09M USD -32.2%
Other Assets, Noncurrent 195K USD -33.2%
Assets 159M USD -29.6%
Accounts Payable, Current 5.34M USD +113%
Accrued Liabilities, Current 16.9M USD +30%
Contract with Customer, Liability, Current 4.85M USD
Liabilities, Current 22.2M USD +43.4%
Operating Lease, Liability, Noncurrent 644K USD -52.1%
Liabilities 22.9M USD +34.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 258K USD
Retained Earnings (Accumulated Deficit) -861M USD -10.8%
Stockholders' Equity Attributable to Parent 136M USD -34.8%
Liabilities and Equity 159M USD -29.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.5M USD +21.2%
Net Cash Provided by (Used in) Financing Activities 208K USD +4.52%
Net Cash Provided by (Used in) Investing Activities 8.68M USD -28.5%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 89.9M shares +1.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.64M USD +12.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23.6M USD +67.5%
Deferred Tax Assets, Valuation Allowance 160M USD +16.2%
Deferred Tax Assets, Gross 161M USD +16%
Operating Lease, Liability 1.34M USD -31.7%
Depreciation 22K USD 0%
Payments to Acquire Property, Plant, and Equipment 27K USD -56.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -82.7M USD +3.24%
Lessee, Operating Lease, Liability, to be Paid 1.44M USD -34.4%
Property, Plant and Equipment, Gross 5.38M USD +0.54%
Operating Lease, Liability, Current 700K USD +12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 467K USD -38.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 781K USD +320%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 95K USD -57.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 467K USD -40.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 467K USD 0%
Operating Lease, Payments 700K USD 0%
Additional Paid in Capital 996M USD +1.03%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 352K USD -21.1%
Share-based Payment Arrangement, Expense 9.59M USD -50.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%